SCHEMBL4860402

SCHEMBL4860402

CCOC(=O)C(C)=Cc1ccc(N)c(O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
MAPT P10636 4/20 0.46
LMNA P02545 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
S1PR4 O95977 1/20 0.46
S1PR1 P21453 1/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 4/20 0.44
TTR P02766 1/20 0.43
DPP4 P27487 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
CYP3A4 P08684 1/20 0.42
GLO1 Q04760 1/20 0.41
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40
PTP4A1 Q93096 1/20 0.39
MIF P14174 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4860394 1.00 KMT2A (0.46) KMT2AMEN1MAPTLMNANPSR1
Hydrochloric Acid SCHEMBL4863994 0.99 KMT2A (0.44) KMT2AMEN1MAPTLMNANPSR1
Hydrochloric Acid SCHEMBL4863455 0.99 KMT2A (0.44) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL11215432 0.89 ALDH1A1 (0.47) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL11215434 0.89 ALDH1A1 (0.47) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL5982543 0.88 MAPT (0.48) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL5982549 0.88 MAPT (0.48) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL9339219 0.80 MEN1 (0.55) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL9339214 0.80 MEN1 (0.55) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL5981582 0.80 GLO1 (0.51) KMT2AMEN1MAPTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234020-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP. 2005-10-20 US claimed
EP-1556059-A1 THROMBOPOIETIN MIMETICS Smithkline Beecham (US) 2005-07-27 EP claimed
WO-2003103686-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-12-18 WO claimed
US-7414040-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2008-08-19 US disclosed
US-20050234020-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP. 2005-10-20 US disclosed
EP-1556059-A1 THROMBOPOIETIN MIMETICS Smithkline Beecham (US) 2005-07-27 EP disclosed
WO-2003103686-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234020-A1 Thrombopoietin mimetics MPL, THPO, TEK KMT2A 1838/4885MEN1 229/4885MAPT 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.